Mortality from Parkinson's disease: A population‐based prospective study (NEDICES)
Identifieur interne : 000286 ( Main/Corpus ); précédent : 000285; suivant : 000287Mortality from Parkinson's disease: A population‐based prospective study (NEDICES)
Auteurs : Ignacio J. Posada ; Julián Benito-Le N ; Elan D. Louis ; Rocío Trincado ; Alberto Villarejo ; María José Medrano ; Félix Bermejo-ParejaSource :
- Movement Disorders [ 0885-3185 ] ; 2011-12.
English descriptors
- KwdEn :
Abstract
Most studies of mortality in Parkinson's disease have been clinical studies, yielding results that are not representative of the general population. We assessed the risk of mortality from Parkinson's disease in the Neurological Disorders in Central Spain (NEDICES) study, a prospective population‐based study in which Parkinson's disease patients who were not ascertained through medical practitioners were also included. The cohort consisted of 5262 elderly subjects (mean baseline age, 73.0 years), including 81 with Parkinson's disease at baseline (1994–1995). Thirteen‐year mortality was assessed. Two thousand seven hundred and one of 5262 subjects (51.3%) died over a median follow‐up of 12.0 years (range, 0.04–14.8 years), including 66 of 81 subjects (81.5%) with Parkinson's disease at baseline and 2635 of 5181 subjects (50.8%) without Parkinson's disease at baseline. In an unadjusted Cox model, the hazard ratio of mortality was increased in subjects with Parkinson's disease (hazard ratio, 2.29; 95% confidence interval, 1.80–2.93; P < .001) versus subjects without Parkinson's disease (reference group). In a Cox model that adjusted for a variety of demographic factors and comorbidities, the risk of mortality remained elevated in subjects with Parkinson's disease (hazard ratio, 1.75; 95% CI, 1.32–2.31, P < .001). In additional Cox models, Parkinson's disease patients with dementia had particularly high risks of mortality (adjusted hazard ratio, 2.62; 95% CI, 1.40–4.90; P < .001). In this prospective population‐based study, Parkinson's disease was an independent predictor of mortality in the elderly. Parkinson's disease patients with dementia had particularly high risks of mortality. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23921
Links to Exploration step
ISTEX:BB974B5A59EFFA3263E9F391A4F0785C6B58D23FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mortality from Parkinson's disease: A population‐based prospective study (NEDICES)</title><author><name sortKey="Posada, Ignacio J" sort="Posada, Ignacio J" uniqKey="Posada I" first="Ignacio J." last="Posada">Ignacio J. Posada</name><affiliation><mods:affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Benito E N, Julian" sort="Benito E N, Julian" uniqKey="Benito E N J" first="Julián" last="Benito-Le N">Julián Benito-Le N</name><affiliation><mods:affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Louis, Elan D" sort="Louis, Elan D" uniqKey="Louis E" first="Elan D." last="Louis">Elan D. Louis</name><affiliation><mods:affiliation>G.H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Trincado, Rocio" sort="Trincado, Rocio" uniqKey="Trincado R" first="Rocío" last="Trincado">Rocío Trincado</name><affiliation><mods:affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Villarejo, Alberto" sort="Villarejo, Alberto" uniqKey="Villarejo A" first="Alberto" last="Villarejo">Alberto Villarejo</name><affiliation><mods:affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Medrano, Maria Jose" sort="Medrano, Maria Jose" uniqKey="Medrano M" first="María José" last="Medrano">María José Medrano</name><affiliation><mods:affiliation>Unit of Vascular Risk Factors, National Center for Epidemiology, ISCIII, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Bermejo Areja, Felix" sort="Bermejo Areja, Felix" uniqKey="Bermejo Areja F" first="Félix" last="Bermejo-Pareja">Félix Bermejo-Pareja</name><affiliation><mods:affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BB974B5A59EFFA3263E9F391A4F0785C6B58D23F</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23921</idno><idno type="url">https://api.istex.fr/document/BB974B5A59EFFA3263E9F391A4F0785C6B58D23F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000286</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Mortality from Parkinson's disease: A population‐based prospective study (NEDICES)</title><author><name sortKey="Posada, Ignacio J" sort="Posada, Ignacio J" uniqKey="Posada I" first="Ignacio J." last="Posada">Ignacio J. Posada</name><affiliation><mods:affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Benito E N, Julian" sort="Benito E N, Julian" uniqKey="Benito E N J" first="Julián" last="Benito-Le N">Julián Benito-Le N</name><affiliation><mods:affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Louis, Elan D" sort="Louis, Elan D" uniqKey="Louis E" first="Elan D." last="Louis">Elan D. Louis</name><affiliation><mods:affiliation>G.H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Trincado, Rocio" sort="Trincado, Rocio" uniqKey="Trincado R" first="Rocío" last="Trincado">Rocío Trincado</name><affiliation><mods:affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Villarejo, Alberto" sort="Villarejo, Alberto" uniqKey="Villarejo A" first="Alberto" last="Villarejo">Alberto Villarejo</name><affiliation><mods:affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Medrano, Maria Jose" sort="Medrano, Maria Jose" uniqKey="Medrano M" first="María José" last="Medrano">María José Medrano</name><affiliation><mods:affiliation>Unit of Vascular Risk Factors, National Center for Epidemiology, ISCIII, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Bermejo Areja, Felix" sort="Bermejo Areja, Felix" uniqKey="Bermejo Areja F" first="Félix" last="Bermejo-Pareja">Félix Bermejo-Pareja</name><affiliation><mods:affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-12">2011-12</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2522">2522</biblScope><biblScope unit="page" to="2529">2529</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">BB974B5A59EFFA3263E9F391A4F0785C6B58D23F</idno><idno type="DOI">10.1002/mds.23921</idno><idno type="ArticleID">MDS23921</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>elderly</term><term>epidemiology</term><term>mortality</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Most studies of mortality in Parkinson's disease have been clinical studies, yielding results that are not representative of the general population. We assessed the risk of mortality from Parkinson's disease in the Neurological Disorders in Central Spain (NEDICES) study, a prospective population‐based study in which Parkinson's disease patients who were not ascertained through medical practitioners were also included. The cohort consisted of 5262 elderly subjects (mean baseline age, 73.0 years), including 81 with Parkinson's disease at baseline (1994–1995). Thirteen‐year mortality was assessed. Two thousand seven hundred and one of 5262 subjects (51.3%) died over a median follow‐up of 12.0 years (range, 0.04–14.8 years), including 66 of 81 subjects (81.5%) with Parkinson's disease at baseline and 2635 of 5181 subjects (50.8%) without Parkinson's disease at baseline. In an unadjusted Cox model, the hazard ratio of mortality was increased in subjects with Parkinson's disease (hazard ratio, 2.29; 95% confidence interval, 1.80–2.93; P < .001) versus subjects without Parkinson's disease (reference group). In a Cox model that adjusted for a variety of demographic factors and comorbidities, the risk of mortality remained elevated in subjects with Parkinson's disease (hazard ratio, 1.75; 95% CI, 1.32–2.31, P < .001). In additional Cox models, Parkinson's disease patients with dementia had particularly high risks of mortality (adjusted hazard ratio, 2.62; 95% CI, 1.40–4.90; P < .001). In this prospective population‐based study, Parkinson's disease was an independent predictor of mortality in the elderly. Parkinson's disease patients with dementia had particularly high risks of mortality. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Ignacio J. Posada MD, PhD</name><affiliations><json:string>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</json:string><json:string>Faculty of Medicine, Complutense University, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Julián Benito‐León MD, PhD</name><affiliations><json:string>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</json:string><json:string>Faculty of Medicine, Complutense University, Madrid, Spain</json:string><json:string>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</json:string></affiliations></json:item><json:item><name>Elan D. Louis MD, MSc</name><affiliations><json:string>G.H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA</json:string><json:string>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA</json:string><json:string>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York, USA</json:string><json:string>Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Rocío Trincado MA</name><affiliations><json:string>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</json:string><json:string>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</json:string></affiliations></json:item><json:item><name>Alberto Villarejo MD</name><affiliations><json:string>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</json:string><json:string>Faculty of Medicine, Complutense University, Madrid, Spain</json:string></affiliations></json:item><json:item><name>María José Medrano MD, PhD</name><affiliations><json:string>Unit of Vascular Risk Factors, National Center for Epidemiology, ISCIII, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Félix Bermejo‐Pareja MD, PhD</name><affiliations><json:string>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</json:string><json:string>Faculty of Medicine, Complutense University, Madrid, Spain</json:string><json:string>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>elderly</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>epidemiology</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>mortality</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><articleId><json:string>MDS23921</json:string></articleId><language><json:string>eng</json:string></language><abstract>Most studies of mortality in Parkinson's disease have been clinical studies, yielding results that are not representative of the general population. We assessed the risk of mortality from Parkinson's disease in the Neurological Disorders in Central Spain (NEDICES) study, a prospective population‐based study in which Parkinson's disease patients who were not ascertained through medical practitioners were also included. The cohort consisted of 5262 elderly subjects (mean baseline age, 73.0 years), including 81 with Parkinson's disease at baseline (1994–1995). Thirteen‐year mortality was assessed. Two thousand seven hundred and one of 5262 subjects (51.3%) died over a median follow‐up of 12.0 years (range, 0.04–14.8 years), including 66 of 81 subjects (81.5%) with Parkinson's disease at baseline and 2635 of 5181 subjects (50.8%) without Parkinson's disease at baseline. In an unadjusted Cox model, the hazard ratio of mortality was increased in subjects with Parkinson's disease (hazard ratio, 2.29; 95% confidence interval, 1.80–2.93; P > .001) versus subjects without Parkinson's disease (reference group). In a Cox model that adjusted for a variety of demographic factors and comorbidities, the risk of mortality remained elevated in subjects with Parkinson's disease (hazard ratio, 1.75; 95% CI, 1.32–2.31, P > .001). In additional Cox models, Parkinson's disease patients with dementia had particularly high risks of mortality (adjusted hazard ratio, 2.62; 95% CI, 1.40–4.90; P > .001). In this prospective population‐based study, Parkinson's disease was an independent predictor of mortality in the elderly. Parkinson's disease patients with dementia had particularly high risks of mortality. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>7.86</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1740</abstractCharCount><pdfWordCount>4860</pdfWordCount><pdfCharCount>32455</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>250</abstractWordCount></qualityIndicators><title>Mortality from Parkinson's disease: A population‐based prospective study (NEDICES)</title><genre><json:string>article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>8</total><last>2529</last><first>2522</first></pages><issn><json:string>0885-3185</json:string></issn><issue>14</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23921</json:string></doi><id>BB974B5A59EFFA3263E9F391A4F0785C6B58D23F</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/BB974B5A59EFFA3263E9F391A4F0785C6B58D23F/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/BB974B5A59EFFA3263E9F391A4F0785C6B58D23F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/BB974B5A59EFFA3263E9F391A4F0785C6B58D23F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Mortality from Parkinson's disease: A population‐based prospective study (NEDICES)</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Funding agencies: This work was supported by FIS 93/0773 and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.</note><note type="content">*Relevant conflicts of interest/financial disclosures: Julián Benito‐León is supported by NIH R01 NS039422 from the National Institutes of Health (Bethesda, MD). Elan Louis is supported by R01 NS042859 and R01 NS039422 from the National Institutes of Health (Bethesda, MD). Félix Bermejo‐Pareja is supported by NIH R01 NS039422 from the National Institutes of Health (Bethesda, MD).</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Mortality from Parkinson's disease: A population‐based prospective study (NEDICES)</title><author><persName><forename type="first">Ignacio J.</forename><surname>Posada</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</affiliation><affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</affiliation></author><author><persName><forename type="first">Julián</forename><surname>Benito‐León</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Avda. de la Constitución 73, portal 3, 7° Izquierda, E‐28821 Coslada, Madrid, Spain</p></note><affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</affiliation><affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</affiliation><affiliation>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</affiliation></author><author><persName><forename type="first">Elan D.</forename><surname>Louis</surname></persName><roleName type="degree">MD, MSc</roleName><affiliation>G.H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA</affiliation><affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA</affiliation><affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York, USA</affiliation><affiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA</affiliation></author><author><persName><forename type="first">Rocío</forename><surname>Trincado</surname></persName><roleName type="degree">MA</roleName><affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</affiliation><affiliation>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</affiliation></author><author><persName><forename type="first">Alberto</forename><surname>Villarejo</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</affiliation><affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</affiliation></author><author><persName><forename type="first">María José</forename><surname>Medrano</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Unit of Vascular Risk Factors, National Center for Epidemiology, ISCIII, Madrid, Spain</affiliation></author><author><persName><forename type="first">Félix</forename><surname>Bermejo‐Pareja</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</affiliation><affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</affiliation><affiliation>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-12"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2522">2522</biblScope><biblScope unit="page" to="2529">2529</biblScope></imprint></monogr><idno type="istex">BB974B5A59EFFA3263E9F391A4F0785C6B58D23F</idno><idno type="DOI">10.1002/mds.23921</idno><idno type="ArticleID">MDS23921</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Most studies of mortality in Parkinson's disease have been clinical studies, yielding results that are not representative of the general population. We assessed the risk of mortality from Parkinson's disease in the Neurological Disorders in Central Spain (NEDICES) study, a prospective population‐based study in which Parkinson's disease patients who were not ascertained through medical practitioners were also included. The cohort consisted of 5262 elderly subjects (mean baseline age, 73.0 years), including 81 with Parkinson's disease at baseline (1994–1995). Thirteen‐year mortality was assessed. Two thousand seven hundred and one of 5262 subjects (51.3%) died over a median follow‐up of 12.0 years (range, 0.04–14.8 years), including 66 of 81 subjects (81.5%) with Parkinson's disease at baseline and 2635 of 5181 subjects (50.8%) without Parkinson's disease at baseline. In an unadjusted Cox model, the hazard ratio of mortality was increased in subjects with Parkinson's disease (hazard ratio, 2.29; 95% confidence interval, 1.80–2.93; P < .001) versus subjects without Parkinson's disease (reference group). In a Cox model that adjusted for a variety of demographic factors and comorbidities, the risk of mortality remained elevated in subjects with Parkinson's disease (hazard ratio, 1.75; 95% CI, 1.32–2.31, P < .001). In additional Cox models, Parkinson's disease patients with dementia had particularly high risks of mortality (adjusted hazard ratio, 2.62; 95% CI, 1.40–4.90; P < .001). In this prospective population‐based study, Parkinson's disease was an independent predictor of mortality in the elderly. Parkinson's disease patients with dementia had particularly high risks of mortality. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>elderly</term></item><item><term>epidemiology</term></item><item><term>mortality</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-04-05">Received</change><change when="2011-07-21">Registration</change><change when="2011-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/BB974B5A59EFFA3263E9F391A4F0785C6B58D23F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="140"><doi origin="wiley" registered="yes">10.1002/mds.v26.14</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">14</numbering></numberingGroup><coverDate startDate="2011-12">December 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="190" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23921</doi><idGroup><id type="unit" value="MDS23921"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2011-04-05"></event><event type="manuscriptRevised" date="2011-07-05"></event><event type="manuscriptAccepted" date="2011-07-21"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2012-01-13"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-09-13"></event><event type="publishedOnlineFinalForm" date="2011-12-14"></event><event type="firstOnline" date="2011-09-13"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2522</numbering><numbering type="pageLast">2529</numbering></numberingGroup><correspondenceTo>Avda. de la Constitución 73, portal 3, 7° Izquierda, E‐28821 Coslada, Madrid, Spain</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23921.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="9"></count><count type="referenceTotal" number="45"></count><count type="wordTotal" number="7946"></count></countGroup><titleGroup><title type="main" xml:lang="en">Mortality from Parkinson's disease: A population‐based prospective study (NEDICES)<link href="#fn1"></link><link href="#fn2"></link><link href="#fn3"></link></title><title type="short" xml:lang="en">Parkinson's Disease and Mortality</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Ignacio J.</givenNames><familyName>Posada</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2 #af3" corresponding="yes"><personName><givenNames>Julián</givenNames><familyName>Benito‐León</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>jbenitol@meditex.es</email></contactDetails></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af4 #af5 #af6 #af7"><personName><givenNames>Elan D.</givenNames><familyName>Louis</familyName><degrees>MD, MSc</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af3"><personName><givenNames>Rocío</givenNames><familyName>Trincado</familyName><degrees>MA</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Alberto</givenNames><familyName>Villarejo</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af8"><personName><givenNames>María José</givenNames><familyName>Medrano</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1 #af2 #af3"><personName><givenNames>Félix</givenNames><familyName>Bermejo‐Pareja</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="ES" type="organization"><unparsedAffiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="ES" type="organization"><unparsedAffiliation>Faculty of Medicine, Complutense University, Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="ES" type="organization"><unparsedAffiliation>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>G.H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="ES" type="organization"><unparsedAffiliation>Unit of Vascular Risk Factors, National Center for Epidemiology, ISCIII, Madrid, Spain</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">elderly</keyword><keyword xml:id="kwd2">epidemiology</keyword><keyword xml:id="kwd3">mortality</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Most studies of mortality in Parkinson's disease have been clinical studies, yielding results that are not representative of the general population. We assessed the risk of mortality from Parkinson's disease in the Neurological Disorders in Central Spain (NEDICES) study, a prospective population‐based study in which Parkinson's disease patients who were not ascertained through medical practitioners were also included. The cohort consisted of 5262 elderly subjects (mean baseline age, 73.0 years), including 81 with Parkinson's disease at baseline (1994–1995). Thirteen‐year mortality was assessed. Two thousand seven hundred and one of 5262 subjects (51.3%) died over a median follow‐up of 12.0 years (range, 0.04–14.8 years), including 66 of 81 subjects (81.5%) with Parkinson's disease at baseline and 2635 of 5181 subjects (50.8%) without Parkinson's disease at baseline. In an unadjusted Cox model, the hazard ratio of mortality was increased in subjects with Parkinson's disease (hazard ratio, 2.29; 95% confidence interval, 1.80–2.93; <i>P</i> < .001) versus subjects without Parkinson's disease (reference group). In a Cox model that adjusted for a variety of demographic factors and comorbidities, the risk of mortality remained elevated in subjects with Parkinson's disease (hazard ratio, 1.75; 95% CI, 1.32–2.31, <i>P</i> < .001). In additional Cox models, Parkinson's disease patients with dementia had particularly high risks of mortality (adjusted hazard ratio, 2.62; 95% CI, 1.40–4.90; <i>P</i> < .001). In this prospective population‐based study, Parkinson's disease was an independent predictor of mortality in the elderly. Parkinson's disease patients with dementia had particularly high risks of mortality. © 2011 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Funding agencies</b>: This work was supported by FIS 93/0773 and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.</p></note><note xml:id="fn2"><p><b>Relevant conflicts of interest/financial disclosures</b>: Julián Benito‐León is supported by NIH R01 NS039422 from the National Institutes of Health (Bethesda, MD). Elan Louis is supported by R01 NS042859 and R01 NS039422 from the National Institutes of Health (Bethesda, MD). Félix Bermejo‐Pareja is supported by NIH R01 NS039422 from the National Institutes of Health (Bethesda, MD).</p></note><note xml:id="fn3"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Mortality from Parkinson's disease: A population‐based prospective study (NEDICES)</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Parkinson's Disease and Mortality</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Mortality from Parkinson's disease: A population‐based prospective study (NEDICES)</title></titleInfo><name type="personal"><namePart type="given">Ignacio J.</namePart><namePart type="family">Posada</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</affiliation><affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Julián</namePart><namePart type="family">Benito‐León</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</affiliation><affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</affiliation><affiliation>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</affiliation><description>Correspondence: Avda. de la Constitución 73, portal 3, 7° Izquierda, E‐28821 Coslada, Madrid, Spain</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Elan D.</namePart><namePart type="family">Louis</namePart><namePart type="termsOfAddress">MD, MSc</namePart><affiliation>G.H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA</affiliation><affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA</affiliation><affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York, USA</affiliation><affiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rocío</namePart><namePart type="family">Trincado</namePart><namePart type="termsOfAddress">MA</namePart><affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</affiliation><affiliation>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alberto</namePart><namePart type="family">Villarejo</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</affiliation><affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">María José</namePart><namePart type="family">Medrano</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Unit of Vascular Risk Factors, National Center for Epidemiology, ISCIII, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Félix</namePart><namePart type="family">Bermejo‐Pareja</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, University Hospital “12 de Octubre,” Madrid, Spain</affiliation><affiliation>Faculty of Medicine, Complutense University, Madrid, Spain</affiliation><affiliation>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-12</dateIssued><dateCaptured encoding="w3cdtf">2011-04-05</dateCaptured><dateValid encoding="w3cdtf">2011-07-21</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">9</extent><extent unit="references">45</extent><extent unit="words">7946</extent></physicalDescription><abstract lang="en">Most studies of mortality in Parkinson's disease have been clinical studies, yielding results that are not representative of the general population. We assessed the risk of mortality from Parkinson's disease in the Neurological Disorders in Central Spain (NEDICES) study, a prospective population‐based study in which Parkinson's disease patients who were not ascertained through medical practitioners were also included. The cohort consisted of 5262 elderly subjects (mean baseline age, 73.0 years), including 81 with Parkinson's disease at baseline (1994–1995). Thirteen‐year mortality was assessed. Two thousand seven hundred and one of 5262 subjects (51.3%) died over a median follow‐up of 12.0 years (range, 0.04–14.8 years), including 66 of 81 subjects (81.5%) with Parkinson's disease at baseline and 2635 of 5181 subjects (50.8%) without Parkinson's disease at baseline. In an unadjusted Cox model, the hazard ratio of mortality was increased in subjects with Parkinson's disease (hazard ratio, 2.29; 95% confidence interval, 1.80–2.93; P < .001) versus subjects without Parkinson's disease (reference group). In a Cox model that adjusted for a variety of demographic factors and comorbidities, the risk of mortality remained elevated in subjects with Parkinson's disease (hazard ratio, 1.75; 95% CI, 1.32–2.31, P < .001). In additional Cox models, Parkinson's disease patients with dementia had particularly high risks of mortality (adjusted hazard ratio, 2.62; 95% CI, 1.40–4.90; P < .001). In this prospective population‐based study, Parkinson's disease was an independent predictor of mortality in the elderly. Parkinson's disease patients with dementia had particularly high risks of mortality. © 2011 Movement Disorder Society</abstract><note type="content">*Funding agencies: This work was supported by FIS 93/0773 and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.</note><note type="content">*Relevant conflicts of interest/financial disclosures: Julián Benito‐León is supported by NIH R01 NS039422 from the National Institutes of Health (Bethesda, MD). Elan Louis is supported by R01 NS042859 and R01 NS039422 from the National Institutes of Health (Bethesda, MD). Félix Bermejo‐Pareja is supported by NIH R01 NS039422 from the National Institutes of Health (Bethesda, MD).</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>elderly</topic><topic>epidemiology</topic><topic>mortality</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>14</number></detail><extent unit="pages"><start>2522</start><end>2529</end><total>8</total></extent></part></relatedItem><identifier type="istex">BB974B5A59EFFA3263E9F391A4F0785C6B58D23F</identifier><identifier type="DOI">10.1002/mds.23921</identifier><identifier type="ArticleID">MDS23921</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000286 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000286 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:BB974B5A59EFFA3263E9F391A4F0785C6B58D23F
|texte= Mortality from Parkinson's disease: A population‐based prospective study (NEDICES)
}}
| This area was generated with Dilib version V0.6.23. |  |